Skip to main content
Clinical Trials/NCT06788977
NCT06788977RecruitingNot Applicable

CEFALY Pregnancy Registry

Cefaly Technology2 sites in 1 country550 target enrollmentStarted: November 25, 2024Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
550
Locations
2
Primary Endpoint
Rate of miscarriage per trimester

Study Overview

Brief Summary

This online registry aims to understand the potential benefits and safety of external trigeminal nerve stimulation for the treatment of migraine in pregnant women. Women do not need to use external trigeminal nerve stimulation or any other form of migraine treatment to participate in the registry.

The main question it aims to answer is:

Is external trigeminal nerve stimulation a safe and effective option for migraine treatment during and after pregnancy?

There are no required changes in migraine treatment to participate in this registry. Participants may or may not use external trigeminal nerve stimulation or any other treatment they currently use and may still participate in the registry. There are no clinic or research visits, as the registry is entirely online. Participants will be asked to complete up to six 15- 20-minute surveys over a time period of up to 12 months.

Detailed Description

This will be a prospective research registry from which retrospective research studies will derive. Individuals who are eligible to participate in the CEFALY Pregnancy Registry will be pregnant women who have migraines or headaches. Use of the external Trigeminal Neurostimulation (eTNS) device is not mandatory for participation in the registry, and the registry will include information from individuals who use and do not use eTNS (CEFALY) to treat their migraines or headaches before, during, and after pregnancy.

The ideal candidate for participation will be women within 14 weeks gestation at the time of screening enrollment, as this will minimize any recall bias. However, women in the second and third trimesters during screening and enrollment will not be excluded and may also participate in the registry. The registry will aim to enroll 550 participants per the inclusion and exclusion criteria.

Registry participation, including consent, screening, enrollment, and completion of registry surveys, will be completed online using a confidential survey platform accessed via a publicly available web-based link. Once the simple consent is acknowledged, the potential participant will enter their name, email, phone number and date of birth. The phone number, and email entered are required to conduct the registry data collection process.

Participants will then complete screening questions to assess their eligibility for the registry. If they meet all eligibility requirements, they will be required to upload sufficient evidence of a current intrauterine pregnancy. The registry investigators will verify the uploaded document for accuracy before enrollment. The participant's name and date of birth are required to validate a current pregnancy based on the required uploaded documents during the screening process.

If eligible and documentation of current pregnancy is confirmed, the investigators will enroll the participant in the registry and start the survey process. Enrolled participants who have agreed to participate in the registry will receive an invitation to the requested surveys via automated email and short message service (SMS) text. The links provided in the email and SMS text will automatically direct the participant to the appropriate survey based on the timing of their enrollment, estimated due date, pregnancy status, and date of completion of prior surveys. Before each survey attempt, enrolled participants will need to verify their identity with an automated authentication code provided to their registered email address and phone number they provided during initial screening to verify their data and protect their entered health information.

Study Design

Study Type
Observational
Observational Model
Other
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to 44 Years (Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients willing and able to provide simple consent for registry participation.
  • Has access to email, text messages via smartphone or computer with internet access
  • Be between the ages of 18 to 44 years at enrollment.
  • Pregnant with one fetus/baby at time of enrollment (singleton pregnancy)
  • Have headaches or migraines prior to pregnancy and continued to have headaches or migraines into pregnancy OR headaches or migraines began while pregnant in the first trimester.
  • Able to provide proof of active intrauterine pregnancy and estimated due date, via online document upload, using any of the following documents:
  • ultrasound report of current pregnancy
  • beta hcg lab report
  • a signed provider's medical documentation confirming intrauterine pregnancy with fetal heart sounds and estimated due date
  • a signed provider's note on a prescription sheet or physician letterhead confirming intrauterine pregnancy and estimated due date

Exclusion Criteria

  • Patients under the age of 18 or over the age of 44 at enrollment
  • Not pregnant at time of enrollment
  • Pregnant with more than one fetus/baby at time of enrollment (multigestational pregnancy)
  • Patients with any other condition which might preclude participation in the opinion of the patient's physician(s) or the study's principal investigator
  • No access to email, smartphone, or computer with internet access

Arms & Interventions

External Trigeminal Nerve Stimulation (eTNS) group

This group reflects participants who are already using eTNS therapy during the pregnancy, as well as participants who start using eTNS therapy at any point during their pregnancy.

Any participant may opt to continue or discontinue eTNS treatments during the registry period, which will not affect their ability to participate.

Intervention: external Trigeminal Nerve Stimulation (Device)

Non-eTNS group

This group reflects participants who have not used eTNS therapy during and throughout their pregnancy. If a participant who initially does not use eTNS therapy during pregnancy decides to start eTNS therapy at any point during their pregnancy, they will be assigned to the eTNS group.

Outcomes

Primary Outcomes

Rate of miscarriage per trimester

Time Frame: through study completion average 2 years

Postpartum Bonding according to the Maternal-to-Infant Bonding Scale

Time Frame: through study completion average 2 years

The "Maternal-to-Infant Bonding Scale" is a scale which measures the mother's feelings regarding her child within the first few weeks after birth. The score of teh scale can range from 0 which denotes favorable or good outcome whereas the maximum score is 24 indicating a poor outcome.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials